| __timestamp | BioMarin Pharmaceutical Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 1643000000 |
| Thursday, January 1, 2015 | 402271000 | 1532000000 |
| Friday, January 1, 2016 | 476593000 | 1364000000 |
| Sunday, January 1, 2017 | 554336000 | 1334000000 |
| Monday, January 1, 2018 | 604353000 | 1484000000 |
| Tuesday, January 1, 2019 | 680924000 | 1638000000 |
| Wednesday, January 1, 2020 | 737669000 | 1726000000 |
| Friday, January 1, 2021 | 759375000 | 2001000000 |
| Saturday, January 1, 2022 | 854009000 | 2009000000 |
| Sunday, January 1, 2023 | 937300000 | 2151000000 |
| Monday, January 1, 2024 | 1009025000 | 2318000000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Zoetis Inc. and BioMarin Pharmaceutical Inc. have shown distinct approaches to handling these costs. From 2014 to 2023, Zoetis Inc. consistently reported higher SG&A expenses, peaking at approximately $2.15 billion in 2023. In contrast, BioMarin's expenses grew steadily, reaching around $937 million in the same year. Despite Zoetis's higher absolute costs, their expenses as a percentage of revenue have remained relatively stable, indicating efficient cost management. Meanwhile, BioMarin's expenses have increased by over 200% since 2014, reflecting their aggressive growth strategy. This data provides a fascinating insight into how these two industry leaders balance cost management with growth ambitions.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Summit Therapeutics Inc.
Zoetis Inc. vs BioMarin Pharmaceutical Inc.: Annual Revenue Growth Compared
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
BioMarin Pharmaceutical Inc. and Jazz Pharmaceuticals plc: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alkermes plc
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Mesoblast Limited
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends